300 related articles for article (PubMed ID: 27376400)
1. Apatinib for the treatment of gastric cancer.
Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
[TBL] [Abstract][Full Text] [Related]
2. Apatinib for molecular targeted therapy in tumor.
Zhang H
Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
[TBL] [Abstract][Full Text] [Related]
3. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
4. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
5. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
Scott AJ; Messersmith WA; Jimeno A
Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival with regorafenib in gastric cancer.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e323. PubMed ID: 27375105
[No Abstract] [Full Text] [Related]
7. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
9. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
10. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
de Mello RA; de Oliveira J; Antoniou G
Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
[No Abstract] [Full Text] [Related]
12. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
13. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
[TBL] [Abstract][Full Text] [Related]
14. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M
Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
16. Study on the clinical effects of targeted therapy on elderly patients with gastric cancer.
Gao L; Li W; Liu Y; Zhang C; Gao W; Wang L
Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2041-2045. PubMed ID: 34862871
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
Fan M; Zhang J; Wang Z; Wang B; Zhang Q; Zheng C; Li T; Ni C; Wu Z; Shao Z; Hu X
Breast Cancer Res Treat; 2014 Jan; 143(1):141-51. PubMed ID: 24292957
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]